ScripVenture capital investment in biopharmaceutical companies ticked higher in the first quarter of 2024. In the second quarter, money is flowing into VC investors and funds focused specifically on the li
ScripLightstone Ventures has closed its third fund – its largest to date – with $375m to fund early stage biopharmaceutical and medical technology companies after several successful exits via initial publi